RedHill Biopharma (RDHL) Asset Writedowns and Impairment (2017 - 2022)
RedHill Biopharma (RDHL) posted quarterly Asset Writedowns and Impairment of $1.5 million for Q4 2022, down 85.88% year-over-year from $10.7 million in Q4 2021, and down 5.25% quarter-over-quarter from $1.6 million in Q3 2022.
RedHill Biopharma (RDHL) Asset Writedowns and Impairment (2017 - 2022) Analysis & Trends
RedHill Biopharma (RDHL) has reported Asset Writedowns and Impairment for 4 consecutive years, with $1.5 million the latest figure, recorded in Q4 2022.
- In Q4 2022, Asset Writedowns and Impairment fell 85.88% year-over-year to $1.5 million; the TTM figure through Dec 2022 stood at $6.0 million (down 62.93% YoY), while the FY2022 annual figure was $6.0 million, down 62.93% from the prior year.
- Asset Writedowns and Impairment retreated to $1.5 million in Q4 2022 per RDHL's latest filing, from $1.6 million in the prior quarter.
- Across five years, Asset Writedowns and Impairment topped out at $10.7 million in Q4 2021 and bottomed at $1.1 million in Q1 2020.
- Historically, Asset Writedowns and Impairment has averaged $2.4 million across 3 years, with a median of $1.8 million in 2020.
- Annual changes were most pronounced in 2021 — Asset Writedowns and Impairment surged 417.28% — and 2022, when it sank 85.88%.
- RedHill Biopharma's Asset Writedowns and Impairment stood at $2.1 million in 2020, then soared by 417.28% to $10.7 million in 2021, then tumbled by 85.88% to $1.5 million in 2022.
- Business Quant data shows RDHL's Asset Writedowns and Impairment at $1.5 million in Q4 2022, $1.6 million in Q3 2022, and $1.3 million in Q2 2022.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 43.83 Bn | 42.86 Bn | - |
| 2 | Teva Pharmaceutical Industries | 42.87 Bn | 39.22 Bn | 2.15 Bn |
| 3 | Zoetis | 31.41 Bn | 29.73 Bn | 1.05 Bn |
| 4 | Takeda Pharmaceutical | 28.55 Bn | 22.75 Bn | 5.10 Bn |
| 5 | United Therapeutics | 22.08 Bn | 19.42 Bn | 683.80 Mn |
| 6 | Viatris | 18.73 Bn | 17.84 Bn | 1.46 Bn |
| 7 | Neurocrine Biosciences | 15.44 Bn | 15.05 Bn | 935.80 Mn |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.94 Bn | - |
| 10 | RedHill Biopharma | 2.05 Bn | 2.05 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2022 | 1.52 Mn |
| Dec 31, 2022 | 1.52 Mn |
| Sep 30, 2022 | 1.60 Mn |
| Sep 30, 2022 | 1.60 Mn |
| Jun 30, 2022 | 1.30 Mn |
| Jun 30, 2022 | 1.30 Mn |
| Mar 31, 2022 | 1.60 Mn |
| Mar 31, 2022 | 1.60 Mn |
| Dec 31, 2021 | 10.74 Mn |
| Dec 31, 2021 | 10.74 Mn |
| Sep 30, 2021 | 1.83 Mn |
| Sep 30, 2021 | 1.83 Mn |
| Jun 30, 2021 | 1.83 Mn |
| Jun 30, 2021 | 1.83 Mn |
| Mar 31, 2021 | 1.83 Mn |
| Mar 31, 2021 | 1.83 Mn |
| Dec 31, 2020 | 2.08 Mn |
| Dec 31, 2020 | 2.08 Mn |
| Sep 30, 2020 | 2.11 Mn |
| Sep 30, 2020 | 2.11 Mn |